4D Molecular Therapeutics Inc Stock

$3.85

1.32% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US35104E1001

Symbol

FDMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

4D Molecular Therapeutics Inc Stock price

$3.85

-19.15 83.26% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.05 1.32%

ISIN

US35104E1001

Symbol

FDMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$178.35m
Enterprise Value	$-119.24m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.76
EV/Sales (TTM) EV/Sales	-5,962.00
P/S ratio (TTM) P/S ratio	8,917.50
P/B ratio (TTM) P/B ratio	0.38
Revenue (TTM) Revenue	$20.00k
EBIT (operating result TTM) EBIT	$-203.33m
Free Cash Flow (TTM) Free Cash Flow	$-156.96m
Cash position	$321.44m
EPS (TTM) EPS	$-3.37
P/E forward	negative
P/S forward	46.05
EV/Sales forward	negative
Short interest	11.33%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

4D Molecular Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

9x Buy

75%

2x Hold

17%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

Buy

75%

Hold

17%

Sell

Analyst Estimates with Stock Price Targets

Financial data from 4D Molecular Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	0.02 0.02	100% 100% 100%
- Direct Costs	6.87 6.87	22% 22% 34,350%
Gross Profit	-6.84 -6.84	142% 142% -34,200%
- Selling and Administrative Expenses	35 35	54% 54% 177,450%
- Research and Development Expense	154 154	67% 67% 770,650%
EBITDA	-196 -196	98% 98% -982,300%
- Depreciation and Amortization	6.87 6.87	22% 22% 34,350%
EBIT (Operating Income) EBIT	-203 -203	94% 94% -1,016,630%
Net Profit	-176 -176	84% 84% -882,200%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

4D Molecular Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

4 days ago

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company's board of...

Neutral

GlobeNewsWire

●

12 days ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2025 financial results, provided operational highlights and outlined exp...

Neutral

GlobeNewsWire

●

16 days ago

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor co...

More 4D Molecular Therapeutics Inc News

Company Profile

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for optalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Head office	United States
CEO	David Kirn
Employees	227
Founded	2013
Website	www.4dmoleculartherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now